Last updated: July 31, 2026
NEUROLITE is a mature nuclear-medicine product containing technetium Tc 99m bicisate, also known as ethyl cysteinate dimer or ECD. It is used with single-photon emission computed tomography to assess regional cerebral perfusion in adults with stroke and other cerebrovascular disorders. The product is commercially established but financially opaque because Lantheus Holdings does not disclose NEUROLITE revenue as a standalone reporting line.
Its market position depends on radiopharmaceutical infrastructure, technetium-99m availability, hospital nuclear-medicine volumes, reimbursement, and competition from other cerebral-perfusion imaging agents. The main commercial risk is long-term substitution by newer imaging modalities and broader use of fluorine-18 PET agents, rather than a near-term biosimilar or conventional generic threat.
What is NEUROLITE and how is it used?
NEUROLITE is a diagnostic radiopharmaceutical kit for the preparation of technetium Tc 99m bicisate injection. The drug crosses the blood-brain barrier and distributes in proportion to cerebral blood flow. The labeled indication is brain imaging in adults with stroke and other cerebrovascular disorders.
The product is supplied as a nonradioactive kit. A radiopharmacy adds sodium pertechnetate Tc 99m before administration. The finished product must be used within the limits established in the FDA prescribing information because technetium-99m has a short physical half-life of approximately six hours.[1]
| Attribute |
NEUROLITE |
| Active imaging agent |
Technetium Tc 99m bicisate |
| Chemical name |
Ethyl cysteinate dimer, or ECD |
| Dosage form |
Kit for preparation of an intravenous injection |
| Imaging modality |
SPECT |
| Primary clinical use |
Cerebral perfusion imaging |
| FDA pathway |
New drug application |
| Product type |
Diagnostic radiopharmaceutical |
| Administration |
Intravenous |
| Commercial constraint |
Requires access to Tc 99m and radiopharmacy preparation |
| Biosimilar exposure |
None |
| Financial disclosure |
No separately reported NEUROLITE revenue |
Who owns and markets NEUROLITE?
Lantheus Holdings is the current commercial owner associated with NEUROLITE in the U.S. market. Lantheus operates in diagnostic imaging and radiopharmaceuticals, with a portfolio that includes contrast agents, PET products, radiopharmaceutical products, and imaging technologies.[2]
NEUROLITE is a legacy product rather than a principal growth driver in Lantheus's public investor disclosures. Lantheus reports financial performance at the company and broader product-category level. It does not provide a separate annual revenue figure, gross margin, operating profit, or unit-volume disclosure for NEUROLITE.
That reporting structure prevents a precise calculation of:
- NEUROLITE annual sales;
- product-level revenue growth;
- NEUROLITE gross margin;
- revenue contribution as a percentage of Lantheus sales;
- U.S. versus international sales;
- sales by stroke, cerebrovascular, or other imaging use.
What is the financial trajectory of NEUROLITE?
NEUROLITE has the financial profile of a mature diagnostic product. Its likely trajectory is characterized by stable or declining procedure-driven demand, limited pricing expansion, and relatively low incremental development spending compared with newer radiopharmaceutical products.
The product can generate recurring revenue because cerebral-perfusion SPECT remains available in hospitals and outpatient imaging centers. Its economics are supported by an installed base of gamma cameras and existing radiopharmacy workflows. Those advantages are offset by the product's dependence on daily isotope logistics and by competition from alternative imaging procedures.
Lantheus's consolidated growth has been driven mainly by newer products and platforms rather than by NEUROLITE. The company's public growth narrative has emphasized products such as DEFINITY, PYLARIFY, and other radiopharmaceutical or diagnostic technologies.[2][3] NEUROLITE therefore has a limited role in the company's reported expansion, even if it remains commercially useful as part of the legacy portfolio.
| Financial factor |
Likely effect on NEUROLITE |
| Product maturity |
Limits volume growth and pricing leverage |
| Established hospital use |
Supports recurring demand |
| Existing SPECT infrastructure |
Reduces adoption friction |
| Tc 99m supply |
Creates operational and logistics exposure |
| Competition from PET |
Applies long-term demand pressure |
| No separately reported sales |
Prevents precise valuation |
| Limited new clinical development |
Reduces expense burden but limits growth |
| Radiopharmacy preparation |
Adds operational complexity |
| Reimbursement changes |
Can affect procedure volume and utilization |
How large is the NEUROLITE market?
A reliable standalone NEUROLITE market-size estimate is not publicly disclosed. Market research reports generally aggregate technetium-based SPECT agents, nuclear cardiology products, neuroimaging agents, or broader radiopharmaceutical categories rather than report product-specific revenue.
The addressable market is narrower than the total nuclear-imaging market. It is limited to cerebral-perfusion imaging procedures in which a technetium-based SPECT agent is selected. Demand is shaped by:
- The number of hospitals and imaging centers operating SPECT equipment.
- Referrals for acute or subacute cerebrovascular evaluation.
- Local availability of PET imaging.
- Radiopharmacy access and technetium-99m supply.
- Reimbursement for cerebral-perfusion SPECT.
- Physician preference and institutional protocols.
NEUROLITE does not directly benefit from growth in oncology PET unless that growth increases overall institutional investment in nuclear medicine. The product competes within a more mature segment than fluorine-18-based oncology imaging.
What drives demand for NEUROLITE?
Cerebrovascular imaging
Cerebral-perfusion imaging can help evaluate perfusion abnormalities in patients with stroke or other cerebrovascular disorders. Its use is linked to clinical protocols, local expertise, and the availability of alternative imaging methods such as CT perfusion, MR perfusion, and PET.
SPECT equipment and radiopharmacy access
NEUROLITE can be used at institutions that already have gamma-camera infrastructure. This supports access in centers that do not operate PET scanners. The requirement for radiopharmacy preparation remains a practical barrier for smaller facilities.
Technetium-99m availability
Technetium-99m is typically supplied through molybdenum-99/technetium-99m generator systems or centralized radiopharmacies. Supply interruptions, generator constraints, transport delays, and local preparation capacity can reduce procedure volumes. The drug's short-lived isotope component also prevents conventional inventory accumulation.
Reimbursement
Reimbursement is tied to the imaging procedure rather than to a conventional retail prescription model. Hospitals and imaging centers account for the radiopharmaceutical, technical component, professional interpretation, and facility costs within applicable Medicare and commercial reimbursement frameworks. Changes in payment rates or utilization policies can affect demand even when the NEUROLITE list price is unchanged.[4]
How does NEUROLITE compare with competing cerebral-perfusion agents?
NEUROLITE competes mainly with other SPECT agents and alternative imaging modalities.
| Technology or product |
Modality |
Commercial comparison with NEUROLITE |
| Tc 99m bicisate, NEUROLITE |
SPECT |
Established cerebral-perfusion agent; depends on Tc 99m |
| Tc 99m exametazime |
SPECT |
Alternative technetium-based cerebral-perfusion agent |
| CT perfusion |
CT |
Widely available and integrated with acute stroke workflows |
| MR perfusion |
MRI |
Provides complementary structural and perfusion information but has access and scheduling constraints |
| F-18 PET agents |
PET |
Higher-resolution or disease-specific applications; greater infrastructure requirements |
| FDG PET |
PET |
Used for metabolic imaging and selected neurologic indications, not as a direct substitute in every use |
The strongest competitive pressure comes from CT perfusion and MR-based protocols in acute stroke, where speed and integration with emergency-care pathways are important. PET creates a longer-term competitive threat in specialized neurologic imaging but requires more expensive equipment and isotope logistics.
NEUROLITE retains a role where SPECT infrastructure is available, PET access is limited, and clinicians use established cerebral-perfusion protocols.
What is the FDA regulatory status of NEUROLITE?
NEUROLITE is an FDA-approved prescription diagnostic product. The FDA-approved labeling identifies the product as a kit for the preparation of technetium Tc 99m bicisate injection for brain imaging in adults with stroke and other cerebrovascular disorders.[1]
The regulatory profile is mature:
- It is not a biologic.
- It is not subject to biosimilar competition.
- It is not a therapeutic small molecule requiring chronic administration.
- Its clinical value is linked to imaging performance and procedural use.
- Its radioisotope component is prepared immediately before administration.
- Safety considerations include hypersensitivity reactions, radiation exposure, and technical issues associated with radiopharmaceutical handling.
FDA labeling also establishes preparation, storage, quality-control, and administration requirements. Manufacturing and distribution must comply with applicable drug, radiopharmaceutical, and radioactive-material requirements.
What patents protect NEUROLITE?
The commercial protection for NEUROLITE is unlikely to depend on an active, product-specific patent exclusivity position. The product was approved decades ago, and any original composition, formulation, or use patents would generally have expired under ordinary U.S. patent-term rules unless later-issued patents or extensions applied.
The main commercial barriers are operational rather than patent-based:
- proprietary or difficult-to-replicate manufacturing know-how;
- validated kit production;
- radiochemical quality controls;
- regulatory compliance;
- reliable technetium-99m supply;
- radiopharmacy distribution;
- hospital purchasing relationships;
- product familiarity among nuclear-medicine physicians.
A current patent-based revenue forecast should not assume meaningful remaining exclusivity without a verified, live patent family covering the marketed product. The FDA Orange Book and USPTO records are the relevant sources for confirming any listed patents, expiration dates, pediatric extensions, or patent-term adjustments.[5][6]
How strong is the NEUROLITE commercial moat?
NEUROLITE has a moderate operational moat and a weak apparent patent moat.
Sources of commercial durability
- Longstanding FDA approval.
- Established SPECT use.
- Existing institutional protocols.
- Familiarity among radiologists and nuclear-medicine physicians.
- Integration with radiopharmacy supply chains.
- Regulatory burden associated with radiopharmaceutical manufacturing.
- Need for validated preparation and quality control.
Sources of vulnerability
- Mature clinical category.
- Limited differentiation from alternative Tc 99m cerebral-perfusion agents.
- Competition from CT and MR perfusion.
- Potential shift toward PET in specialized neurology.
- Dependence on isotope supply and same-day distribution.
- Limited public evidence of major new clinical development.
- No disclosed product-level growth program.
The product can remain profitable even without strong patent protection because manufacturing, regulatory, and distribution requirements raise the practical barriers to entry. Those barriers do not eliminate competition, but they can slow substitution by smaller manufacturers.
Are generic or 505(b)(2) launch risks significant?
The conventional generic risk is lower than for a standard oral tablet because NEUROLITE is a radiopharmaceutical kit with specialized preparation and quality requirements. A competing applicant would need to demonstrate pharmaceutical equivalence, radiochemical performance, stability, labeling compliance, and manufacturing control.
Potential entry routes could include:
- an abbreviated new drug application for a therapeutically equivalent product;
- a 505(b)(2) application relying partly on established clinical and regulatory information;
- a competing technetium-based cerebral-perfusion agent with different formulation or labeling;
- institutional substitution toward another imaging modality.
No biosimilar pathway applies because NEUROLITE is not a biologic. Paragraph IV litigation is therefore relevant only if a generic or 505(b)(2) applicant challenges an unexpired listed patent. Given the age of the product, the principal risk is likely regulatory and commercial substitution rather than a high-value patent challenge.
What is the licensing and transaction history?
NEUROLITE's current commercial economics are linked to portfolio ownership and product commercialization arrangements rather than to a high-profile current licensing program. Public company filings should be reviewed for acquisition terms, product-transfer agreements, royalty obligations, and rights by geographic territory.
Lantheus's investor materials focus on the company's broader diagnostic-imaging portfolio. NEUROLITE is not generally presented as a principal transaction asset or a major platform product.[2][3] That supports a valuation view in which the product has residual cash-flow value but limited strategic influence over the company's enterprise valuation.
What litigation affects NEUROLITE?
No major current patent litigation materially defining the NEUROLITE market is widely identified in the core public sources used for product and company analysis. Litigation exposure is more likely to arise from:
- product liability;
- radiopharmaceutical handling;
- manufacturing or supply disputes;
- reimbursement disputes;
- contract and distribution matters;
- regulatory compliance.
A meaningful Paragraph IV case would require a current Orange Book-listed patent and an ANDA applicant's certification challenging that patent. The commercial relevance of any such case would depend on the patent's remaining term, the scope of the claims, the applicant's launch strategy, and whether a settlement imposed a delayed-entry date.
What generic launch scenarios exist for NEUROLITE?
| Scenario |
Market effect |
| No competing product |
NEUROLITE retains established demand with gradual category decline |
| Single approved competitor |
Hospital and radiopharmacy price pressure increases |
| Multiple Tc 99m competitors |
Faster price erosion and formulary substitution |
| Shift to CT/MR perfusion |
Procedure volume declines independent of generic entry |
| Increased PET adoption |
Higher substitution in specialized neurologic imaging |
| Tc 99m supply disruption |
Temporary volume loss and possible protocol switching |
| Manufacturing interruption |
Short-term shortages and loss of institutional confidence |
The most credible base case is continued availability with modest demand erosion rather than an abrupt patent-driven collapse. Radiopharmaceutical markets often change through procurement decisions, isotope access, and imaging-protocol substitution rather than through a single generic launch event.
What is the geographic outlook for NEUROLITE?
The United States remains the most commercially important market because of its established nuclear-medicine infrastructure, reimbursement system, and Lantheus distribution position. International demand depends on national radiopharmaceutical regulation, local isotope supply, hospital SPECT penetration, and reimbursement.
Geographic barriers include:
- radioactive-material licensing;
- short product-use windows;
- cross-border transport restrictions;
- local radiopharmacy requirements;
- national pricing controls;
- different clinical standards for stroke imaging.
The short half-life of Tc 99m makes local or regional production and distribution more important than conventional pharmaceutical export logistics.
Key Takeaways
- NEUROLITE is a mature Tc 99m bicisate SPECT product for cerebral-perfusion imaging.
- Lantheus is the principal U.S. commercial owner associated with the product.
- Lantheus does not publicly disclose NEUROLITE revenue, margins, or unit volumes separately.
- The product's financial trajectory is likely stable to declining, with recurring procedural revenue but limited growth.
- The strongest competitive threats are CT perfusion, MR perfusion, and selected PET applications.
- Biosimilar risk does not apply.
- Generic and 505(b)(2) risks are constrained by radiopharmaceutical manufacturing, quality-control, isotope-supply, and distribution requirements.
- Patent protection is unlikely to be the primary current commercial moat for a product approved decades ago.
- The principal value drivers are operational reliability, radiopharmacy access, reimbursement, and institutional protocol retention.
- A product-specific valuation requires nonpublic sales, pricing, gross-margin, and geographic data because public filings do not isolate NEUROLITE economics.
FAQs About NEUROLITE Market and Financial Outlook
Is NEUROLITE still FDA approved?
Yes. NEUROLITE remains an FDA-approved kit for preparing technetium Tc 99m bicisate injection for adult brain imaging in stroke and other cerebrovascular disorders.[1]
Does NEUROLITE have biosimilar competition?
No. NEUROLITE is a radiopharmaceutical drug product, not a biologic. Biosimilar competition is not applicable.
Does Lantheus disclose NEUROLITE sales?
No. Lantheus reports consolidated and portfolio-level financial results but does not publish a separate NEUROLITE revenue figure.
Is NEUROLITE protected by active patents?
The product's original patent protection would generally be expected to have expired given its long commercial history. Current protection must be confirmed through live patent and Orange Book records rather than assumed from historical exclusivity.
What is the largest long-term risk to NEUROLITE demand?
The largest long-term risk is substitution of cerebral-perfusion SPECT by CT perfusion, MR perfusion, or PET-based imaging in clinical settings where those technologies are available and reimbursed.
References
-
U.S. Food and Drug Administration. (n.d.). NEUROLITE: Kit for the preparation of technetium Tc 99m bicisate injection, prescribing information. https://www.accessdata.fda.gov/drugsatfda_docs/label/
-
Lantheus Holdings, Inc. (2024). Annual report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934. U.S. Securities and Exchange Commission. https://www.sec.gov/edgar/browse/?CIK=1521033
-
Lantheus Holdings, Inc. (2024). Investor relations and product portfolio materials. https://www.lantheus.com/investors/
-
Centers for Medicare & Medicaid Services. (2024). Medicare physician fee schedule and hospital outpatient prospective payment system. https://www.cms.gov/medicare/payment
-
U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations, Orange Book. https://www.fda.gov/drugs/drug-approvals-and-databases/approved-drug-products-therapeutic-equivalence-evaluations-orange-book
-
United States Patent and Trademark Office. (n.d.). Patent Center. https://patentcenter.uspto.gov/
